Newswise — PLYMOUTH MEETING, PA [November 1, 2018] — The National Comprehensive Cancer Network® (NCCN®) today announced a new agreement with Syapse, the leading precision medicine company, to expand the use of best practices in precision medicine when treating people with cancer. Syapse delivers solutions for scaling enterprise precision oncology programs. The data contained in the NCCN Biomarkers Compendium® will strengthen Syapse’s decision support and workflow tools, increasing access to more personalized care.
“Treatment recommendations for people with cancer are expanding and improving rapidly, and that is particularly the case with precision medicine,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “The experts who sit on the various NCCN Guidelines Panels are at the forefront of advances in using genes and gene products for diagnosis, screening, monitoring, surveillance, and other aspects of cancer care. The latest updates from our guidelines are included in the NCCN Biomarkers Compendium, which will now support the point-of-care decision-making tools from Syapse.”
The NCCN Biomarkers Compendium is part of NCCN’s Library of Compendia, which also includes databases for Drugs & Biologics (NCCN Compendium®), as well as the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™). The NCCN Compendium® is recognized by public and private insurers alike, including CMS and UnitedHealthcare, as an authoritative reference for oncology coverage policy. The recommendations contained in the Library of NCCN Compendia are extracted directly from the relevant NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and are updated on a continuous basis.
“To bring precision medicine to more patients in more places, it is essential for organizations across the healthcare industry to work together,” said Ken Tarkoff, CEO of Syapse. “The NCCN Biomarkers Compendium is universally recognized as the expert resource for genetic testing in patients. We are eager to support our health system oncologists by integrating NCCN’s latest guidelines into the Syapse platform.”
The NCCN-supported data will begin appearing on the Syapse platform in late 2018. Syapse is committed to updating that content weekly to keep pace with the NCCN Guidelines.
“Harnessing technology to share the latest evidence- and expert consensus-based information on biomarkers allows clinicians to make well-informed decisions more efficiently,” said Dr. Carlson. “That means they’ll have more time for the patients who need them.”
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
Syapse is on a mission to deliver the best care for every cancer patient through precision medicine. Our software platform, data sharing network, and industry partnerships enable healthcare providers to bring precision cancer care to every patient who needs it. By bringing together leading healthcare innovators into a unified ecosystem, we are working toward a future in which all cancer patients have access to the best personalized care, regardless of location or income. Our customers—including Aurora Health Care, Catholic Health Initiatives, Dignity Health, Henry Ford Health System, Intermountain Healthcare, Providence St. Joseph Health, and Seoul National University Hospital—manage one million active cancer cases at nearly 300 hospitals in 25 states and South Korea.